Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entity

GenBioPro

Tracked across 2 events · 136 articles · First seen May 01, 2026 · Last active May 15, 2026

Sentiment
0
Attention
6
Events
2
Relationships
16
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 50
Domestic
Impact: GenBioPro, a manufacturer of a generic version of mifepristone, also filed an emergency appeal, contributing to the United States — Supreme Court of the United States's decision to restore access.
May 04, 2026 · 58 articles
6 -50
Regulatory
Impact: GenBioPro, a generic Mifepristone manufacturer, stated that the court's decision ignores the United States — Food and Drug Administration's science and decades of safe use of the drug.
May 01, 2026 · 78 articles
ERGEN INTELLIGENCE
Track GenBioPro live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.